Pharmacogenomic approaches in Alzheimer's disease drug development
Jeroen Aerssens · Drug Development Research · 2002
Abstract The basic principle of pharmacogenomics, namely, the search for a genetic basis that might explain the interindividual variation in drug response, has been around for a long time. Thanks to some recent biotechnological developments and the deliveries of the Human Genome Project, significant progress can now be made. Of particular interest for pharmacogenomics research is the availability of a large number of genetic markers in the human genome that have been identified and can now efficiently be screened for. In addition to new scientific and laboratory tools, successful pharmacogenomics projects also require high‐quality phenotypic data, for which clinical trials provide a unique resource. This review describes how pharmacogenomic approaches can be applied during the discovery and clinical development of new drugs for Alzheimer's disease. Drug Dev. Res. 56:67–73, 2002. © 2002 Wiley‐Liss, Inc.